| |
|
|
 |
|
Future Perspectives of Circulatory Support in Acute Heart Failure: Rationale for a Continuum of Care
Eberhard Grube, MD
RT: 14:32 |
 |
|
Recovering the Dysfunctional Heart in Pre-Shock Conditions: Is it Time for a Paradigm Shift in Management of ACS?
José Henriques, MD
RT: 13:11 |
 |
|
Late Breaking Clinical Trials with Minimally Invasive Circulatory Support Technology: IMPRESS, PROTECT, and RECOVER, what does it all mean?
William O'Neill, MD
RT: 22:12 |
 |
|
The Next Generation of Circulatory Support in the Cath Lab
Simon R. Dixon
RT: 14:03 |
 |
|
Introducing a Minimally Invasive Circulatory Support System in the OR
Erik Wassberg
RT: 15:38 |
Friday, April 27, 2007 |
 |
|
Elective Support in the European CathLab: The Europella Registry
Dr. Henriques - Amsterdam, The Netherlands
RT: 14:44 |
 |
|
Is the Impella LP2.5 the Right Device for Cardiogenic Shock? - Protagonism
Dr. Ferrari - Jena, Germany
RT: 14:54 |
Saturday, April 28, 2007 |
 |
|
Impress, Protect, and Recover with Cardiac Assist Devices: What Does It All Mean?
Dr. Samuels - Philadelphia, PA, USA
RT: 28:31 |
 |
|
Protect I: Feasibility Trial for Impella RECOVER® LP2.5 in Patients Undergoing High Risk PCI
Dr. Kar - Houston, TX, USA
RT: 10:27 |
 |
|
Impella 5.0 LD/LP Recover 1 Trial
Dr. Anderson - New Brunswick, NJ, USA
RT: 12:56 |
 |
|
ISAR-SHOCK Trial: Impella LP2.5 vs IABP in AMI Cardiogenic Shock
Dr. Seyfarth - Munich, Germany
RT: 20:33 |
|
|
AMC MACH 2 Trial: Left Ventricular Support with Impella 2.5 in Acute STEMI
Dr. Henriques - Amsterdam, The Netherlands
RT: 17:47 |
| |
|
The Impella® is an Investigational Device limited by U.S. Federal Law solely for Investigational Use in the United States. |
|
